featured
Bulevirtide Monotherapy in Patients With HDV-Related Compensated Cirrhosis and Clinically Significant Portal Hypertension
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
J. Hepatol. 2022 Dec 01;77(6)1525-1531, E Degasperi, MP Anolli, SC Uceda Renteria, D Sambarino, M Borghi, R Perbellini, C Scholtes, F Facchetti, A Loglio, S Monico, M Fraquelli, A Costantino, F Ceriotti, F Zoulim, P LamperticoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.